8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) (STEMBANCC)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,
StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a we ...
Voir le projet
38
Participants partenaires
TERMINÉ
An integrated approach towards drug discovery and target validation for pain (Decipain)
Date du début: 1 sept. 2012, Date de fin: 31 août 2016,
Chronic and neuropathic pain, usually diagnosed as spontaneous pain, hypersensitivity to pain or both, is a maladaptive response of the organism to injury and inflammation.Finding new effective drugs to treat these debilitating conditions has shown particularly difficult, as compounds showing good efficacy in preclinical models often fail to meet clinical trials endpoints. A commonly accepted expl ...
Voir le projet
1
Participant partenaire
TERMINÉ
Neuroelectronics and nanotechnology: towards a Multidisciplinary Approach for the Science and Engineering of Neuronal Networks (NAMASEN)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2015,
"We identify Neuroelectronics as a novel mature discipline, at the boundaries between neurobiology, electrophysiology, computational neurosciences, microelectronics, materials sciences, and nanotechnologies. In the proposed Marie-Curie consortium, each of these components, as well as the specific application contexts (i.e. basic research, neuroprosthetics, and pharmaceutical applications), are rep ...
Voir le projet
14
Participants partenaires
TERMINÉ
bioMARkers and molecular tumor classification for non-genotoxic CARcinogenesis (MARCAR)
Date du début: 1 janv. 2010, Date de fin: 30 juin 2015,
MARCAR aims to establish reliable early markers and molecular classification of tumors in non genotoxic carcinogenesis, applying a mechanism-based approach. Benefits are improved drug safety, more efficient drug development, and progress with 3 R issues. MARCAR focuses on rodent liver, the major target organ of non-genotoxic carcinogens (NGC). However, this approach will facilitate predictions for ...
Voir le projet
12
Participants partenaires
TERMINÉ
SAFER AND FASTER EVIDENCE-BASED TRANSLATION (SAFE-T)
Date du début: 15 juin 2009, Date de fin: 14 juin 2015,
The public-private consortium composed of complementary SMEs, academic and clinical centers of excellence and EMEA as partner proposes SAFE-T (Safer And Easter Evidence-based Iranslation) project for the establishment of a biomarker (BM) qualification process and its validation in clinical biomarker studies designed for the translation, performance testing and eventual regulatory qualifIcatIon of ...
Voir le projet
26
Participants partenaires
TERMINÉ
Predicting individual response and resistance to VEGFR/mTOR pathway therapeutic intervention using biomarkers discovered through tumour functional genomics (PREDICT)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,
"The strategic development of accurate biomarkers to predict response to therapy in cancer medicine will enhance clinical outcome and reduce the health economic impact of drug resistant disease. The PREDICT consortium will identify and validate predictive biomarkers for two drugs which have direct anti-tumour cell and anti-angiogenic activity and for which no established predictive biomarkers of t ...
Voir le projet
16
Participants partenaires
TERMINÉ
"Spontaneous clearance in Patients acutely infected with HCV - Immune profiling, Novel biomarkers and X-omics approaches" (SPHINX)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2014,
"The proposed project aims to identify novel biomarkers and provide new insight into the mechanisms of spontaneous clearance of hepatitis C virus (HCV) during the early stages of acute infection. Indeed hepatitis C is a major public health problem with high incidence in regions such as Egypt and other Mediterranean Partner Countries (MPCs). Our current application follows from an FP5 project entit ...
Voir le projet
10
Participants partenaires
TERMINÉ
Understanding interactions between cells and nanopatterned surfaces (NanoScale)
Date du début: 1 juil. 2008, Date de fin: 30 juin 2011,
The study of biological processes occurring at the nanoscale is becoming a new discipline at the border between Physics and Biology with major scientific challenges and new technological applications. In fact, interactions at the nanoscale between cells/neurons and surfaces with specific nanopatterns appear to control several major biological processes, such as cell proliferation and differentiati ...
Voir le projet